Shebli Atrash, MD on CAR-T Treatment Affecting Clinicians @atrashshebli @atriumhealth @levinecancer

Shebli Atrash, MD on CAR-T Treatment Affecting Clinicians @atrashshebli @atriumhealth @levinecancer


2 months
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0

Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the COVID-19 pandemic.

Chemeric antigen receptor (CAR)-T-cell therapy has ignited a surge of hope in hematological malignancies, embodied in the positive outcomes of early clinical trials involving pre-B-cell acute lymphoblastic leukemia, B-cell lymphoma and multiple myeloma patients. CAR-T-cell therapy is considered a groundbreaking treatment for immunotherapy, with the ability to cure many hematological cancers. Nevertheless, new problems have arisen as the use of CAR-T-cell therapy has increased. Such challenges include the manufacturing process of the CAR-T cells, the resistance mechanisms that underlie disease relapse, adverse effects and cost. This analysis describes published clinical trial findings as well as planned advances to resolve CAR-T resistance.

Up Next Autoplay